Last mentioned: Mar 3, 2026
FDA Type B Meeting
Planned follow-up meeting to define the Phase III pathway for AMT-130 in Huntington's disease.
AMT-260 Data
Clinical data expected from the Phase I/IIa study in refractory mesial temporal lobe epilepsy.
Earnings Release
Company announces 2025 results and provides update on FDA Type A meeting.
Fiscal Year End
uniQure closes 2025 with $622.5M in cash and equivalents.
uniQure reported a robust $622.5 million cash position, extending its operational runway into late 2029. While clinical data for its Huntington’s disease candidate AMT-130 remains strong, the company is still seeking regulatory alignment with the FDA on a definitive Phase III pathway.
This page surfaces every story mentioning AMT-130 across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where AMT-130 was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |